Next Article in Journal
STAT3: An Anti-Invasive Factor in Colorectal Cancer?
Previous Article in Journal
Cancer Associated Fibroblasts and Tumor Growth: Focus on Multiple Myeloma
Previous Article in Special Issue
The Double-Edged Sword: Conserved Functions of Extracellular Hsp90 in Wound Healing and Cancer
Cancers 2014, 6(3), 1382-1393; doi:10.3390/cancers6031382
Article

Heat Shock Protein 90 (HSP90) and Her2 in Adenocarcinomas of the Esophagus

1
, 1
, 2
, 3
 and 4,*
Received: 16 January 2014; in revised form: 25 April 2014 / Accepted: 16 June 2014 / Published: 27 June 2014
(This article belongs to the Special Issue Heat Shock Proteins in Cancer: Chaperones of Tumorigenesis)
View Full-Text   |   Download PDF [1177 KB, uploaded 27 June 2014]   |   Browse Figures
Abstract: Her2 overexpression and amplification can be found in a significant subset of esophageal adenocarcinomas. The activity of Her2 has been shown to be modulated by molecular chaperones such as HSP90. We analyzed expression/amplification data for HSP90 and Her2 on 127 primary resected esophageal adenocarcinomas in order to evaluate a possible relationship between these two molecules. HSP90 expression determined by immunohistochemistry was observed in various levels. Thirty nine (39) tumors (30.7%) were classified as Her2-positive according to their immunoreactivity and amplification status. There was a significant correlation between HSP90 expression and Her2-status (p = 0.008). This could also be demonstrated by quantitative protein expression analysis with reverse phase protein arrays (r = 0.9; p < 0.001). Her2-status was associated withpT-category (p = 0.041), lymph node metastases (p = 0.049) and tumor differentiation (p = 0.036) with a higher percentage of cases with negative Her2 status in lower tumor stagesA negative Her2-status was also associated with better survival in univariate and multivariate analysis (p = 0.001 and p = 0.014). For HSP90, no associations between clinical and pathological parameters were found. The observed association between HSP90 expression and Her2 suggests a co-regulation of these molecules in at least a subset of esophageal adenocarcinomas. Anti-HSP90 drugs, which recently have been introduced in cancer treatment, may also be an option for these tumors by targeting HSP90 alone or in combination with Her2.
Keywords: HSP90; Her2; esophageal adenocarcinoma; immunohistochemistry; RPPA; in situ hybridization HSP90; Her2; esophageal adenocarcinoma; immunohistochemistry; RPPA; in situ hybridization
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Slotta-Huspenina, J.; Becker, K.-F.; Feith, M.; Walch, A.; Langer, R. Heat Shock Protein 90 (HSP90) and Her2 in Adenocarcinomas of the Esophagus. Cancers 2014, 6, 1382-1393.

AMA Style

Slotta-Huspenina J, Becker K-F, Feith M, Walch A, Langer R. Heat Shock Protein 90 (HSP90) and Her2 in Adenocarcinomas of the Esophagus. Cancers. 2014; 6(3):1382-1393.

Chicago/Turabian Style

Slotta-Huspenina, Julia; Becker, Karl-Friedrich; Feith, Marcus; Walch, Axel; Langer, Rupert. 2014. "Heat Shock Protein 90 (HSP90) and Her2 in Adenocarcinomas of the Esophagus." Cancers 6, no. 3: 1382-1393.


Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert